Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex

Swetha Kambhampati, MD, Sandy W. Wong, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Priya Choudhry, PhD, William Karlon, MD PhD, Arun P. Wiita, MD PhD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-138869

Published: 2020

Journal Articles

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Ian Ferguson, BA, Yu-Hsiu T. Lin, BA, Sami Tuomivaara, PhD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Sandy W. Wong, MD, Nina D. Shah, MD, Christoph Driessen, MD, Brian G. Van Ness, PhD, Arun P. Wiita, MD PhD

Blood (2019) 134 (Supplement_1): 1803.

https://doi.org/10.1182/blood-2019-131681

Published: 2019

Journal Articles

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Jaewoong Lee, PhD, Gang Xiao, PhD, Kadriye Nehir Nehir Cosgun, PhD, Huimin Geng, PhD, Ning Ma, PhD, Lai N Chan, PhD, Kohei Kume, PhD, Matthew Nix, PhD, Zhengshan Chen, MD PhD, Chun-Wei David Chen, PhD, Jianjun Chen, PhD, Vishal Khairnar, PhD, Arun P. Wiita, MD PhD, Andrei Thomas-Tikhonenko, PhD, Michael Farzan, MD PhD, Michael S. Diamond, PhD, Jae U Jung, PhD, Nagarajan Vaidehi, PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 2782.

https://doi.org/10.1182/blood-2019-127615

Published: 2019

Journal Articles

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Lai N Chan, PhD, Mark A. Murakami, MDMA,MMSc, Rebecca Caesar, Christian Hurtz, PhD, Kohei Kume, PhD, Teresa Sadras, PhD, Seyedmehdi Shojaee, PhD, Petri Pölönen, MSc, Amol Ugale, PhD, Jaewoong Lee, PhD, Kadriye Nehir Cosgun, PhD, Huimin Geng, PhD, Merja Heinäniemi, PhD, Olli Lohi, MD PhD, Arun P. Wiita, MD PhD, Shai Izraeli, MD, David M Weinstock, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 3944.

https://doi.org/10.1182/blood-2019-130774

Published: 2019

Journal Articles

In Vitro -Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies

Matthew Nix, PhD, Yu-Hsiu T. Lin, BA, Huimin Geng, PhD, Makeba Marcoulis, BA, Paul Phojanakong, BA, Donghui Wang, BA, Veronica Steri, PhD, Jeffrey Whitman, MD, Sagar Bapat, MD PhD, Elliot Stieglitz, MD, Anne Deucher, MD PhD, Kristie L White, MD MD, Byron C Hann, MD PhD, Arun P. Wiita, MD PhD

Blood (2019) 134 (Supplement_1): 1337.

https://doi.org/10.1182/blood-2019-130938

Published: 2019

Journal Articles

Identifying Factors in Multiple Myeloma Controlling Response to B-Cell Maturation Antigen (BCMA)-Targeted Immunotherapy Using CRISPR-Based Functional Genomics

Poornima Ramkumar, PhD, Jaime Leong, B.S., Meghan Seyler, B.S., Stratton J Georgoulis, Axel Hyrenius Wittsten, PhD, Priya Choudhry, PhD, Kole Roybal, PhD, Arun P Wiita, MD PhD, Martin Kampmann, PhD

Blood (2018) 132 (Supplement 1): 1926.

https://doi.org/10.1182/blood-2018-99-115368

Published: 2018

Journal Articles

Integrating Phosphoproteomics and Transcriptional Classifiers Reveals "Hidden Signaling" in Multiple Myeloma Including Differential KRAS and NRAS Mutant Effects

Yu-Hsiu T. Lin, BA, Gergory P. Way, PhD, Margarette C. Mariano, MS, Makeba Marcoulis, BA, Ian Ferguson, BA, Casey S. Greene, PhD, Arun P Wiita, MD, PhD

Blood (2018) 132 (Supplement 1): 469.

https://doi.org/10.1182/blood-2018-99-113683

Published: 2018

Journal Articles

DNA Methyltransferase Inhibitors Increase Expression of CD38 and Enhance Daratumumab Efficacy in Multiple Myeloma

Priya Choudhry, PhD, Margarette C. Mariano, MS, Arun P Wiita, MD PhD

Blood (2018) 132 (Supplement 1): 5618.

https://doi.org/10.1182/blood-2018-99-114206

Published: 2018

Journal Articles

Defining the Cell Surface Proteome of MLL Rearranged Leukemia

Matthew Nix, PhD, Arun P. Wiita, MD PhD

Blood (2017) 130 (Supplement 1): 3971.

https://doi.org/10.1182/blood.V130.Suppl_1.3971.3971

Published: 2017

Journal Articles

CD74 Is Expressed in Relapsed and Refractory Multiple Myeloma and Can be Targeted with a Novel Anti-CD74 Antibody Drug Conjugate, SΤRO-001

Millicent Embry, Xiaofan Li, PhD, Abigail Yu, PhD, Cristina Abrahams, PhD, Nancy Y. Greenland, MD PhD, Kwun Wah Wen, MD PhD, Chris Jones, Venita DeAlmeida, PhD, Stellanie Krimm, Sarah Krueger, PhD, Shannon Matheny, PhD, Toni Kline, PhD, Alice Yam, PhD, Ryan Stafford, PhD, Arun P. Wiita, MD PhD, Trevor Hallam, PhD, Mark Lupher, PhD, Arturo Molina, MDMS, FACP

Blood (2017) 130 (Supplement 1): 4420.

https://doi.org/10.1182/blood.V130.Suppl_1.4420.4420

Published: 2017

Journal Articles

Unbiased Phosphoproteomics Reveals a Therapeutically Relevant Connection between Pre-mRNA Splicing and Proteasome Inhibition in Multiple Myeloma

Hector H Huang, PhD, Christine YT Lam, BA, Alexis Thornton, BA, Margarette Mariano, MS, Ian Ferguson, BA, Byron C Hann, MD PhD, Angela Brooks, PhD, Arun P. Wiita, MD PhD

Blood (2017) 130 (Supplement 1): 3069.

https://doi.org/10.1182/blood.V130.Suppl_1.3069.3069

Published: 2017

Journal Articles

T Cell Engagement without Cytokine Storm: A Novel Bcma x CD3 Antibody Killing Myeloma Cells with Minimal Cytokine Secretion

Ben Buelow, MD PhD, Duy Pham, Priya Choudhry, PhD, Kevin Dang, Payal Pratap, Starlynn Clarke, PhD, Katherine Harris, PhD, Brett Jorgensen, PhD, Shelley Force Aldred, Ute Schellenberger, PhD, Nina Shah, MD, Nathan Trinklein, PhD, Arun P. Wiita, MD PhD, Suhasini Iyer, PhD, Wim Van Schooten, PhD

Blood (2017) 130 (Supplement 1): 501.

https://doi.org/10.1182/blood.V130.Suppl_1.501.501

Published: 2017

Journal Articles

Tofacitinib Reverses Growth Promoting Effects of the Bone Marrow Stromal Environment Though Inhibition of JAK1/STAT3 Signaling in Multiple Myeloma

Christine Lam, Megan Murnane, M.Sc., Geoffrey A. Smith, Jack Taunton, PhD, Blake T. Aftab, PhD, Arun P. Wiita, MD PhD

Blood (2016) 128 (22): 2098.

https://doi.org/10.1182/blood.V128.22.2098.2098

Published: 2016

Journal Articles

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

Daniel W. Sherbenou, MD PhD, Blake T. Aftab, PhD, Yang Su, PhD, Christopher R. Behrens, PhD, Arun P. Wiita, MD PhD, Aaron C. Logan, MD PhD, Diego Acosta-Alvear, PhD, Byron C. Hann, MD PhD, Peter Walter, PhD, Xiaobo Wu, MD, John P. Atkinson, MD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Bin Liu, PhD

Blood (2016) 128 (22): 384.

https://doi.org/10.1182/blood.V128.22.384.384

Published: 2016

NARROW

Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

In Vitro -Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies

Identifying Factors in Multiple Myeloma Controlling Response to B-Cell Maturation Antigen (BCMA)-Targeted Immunotherapy Using CRISPR-Based Functional Genomics

Integrating Phosphoproteomics and Transcriptional Classifiers Reveals "Hidden Signaling" in Multiple Myeloma Including Differential KRAS and NRAS Mutant Effects

DNA Methyltransferase Inhibitors Increase Expression of CD38 and Enhance Daratumumab Efficacy in Multiple Myeloma

Defining the Cell Surface Proteome of MLL Rearranged Leukemia

CD74 Is Expressed in Relapsed and Refractory Multiple Myeloma and Can be Targeted with a Novel Anti-CD74 Antibody Drug Conjugate, SΤRO-001

Unbiased Phosphoproteomics Reveals a Therapeutically Relevant Connection between Pre-mRNA Splicing and Proteasome Inhibition in Multiple Myeloma

T Cell Engagement without Cytokine Storm: A Novel Bcma x CD3 Antibody Killing Myeloma Cells with Minimal Cytokine Secretion

Tofacitinib Reverses Growth Promoting Effects of the Bone Marrow Stromal Environment Though Inhibition of JAK1/STAT3 Signaling in Multiple Myeloma

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only